Pharsight

Drugs that contain Morphine Sulfate

1. Arymo Er patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549899 ZYLA Abuse deterrent pharmaceutical compositions for controlled release
Jul, 2033

(9 years from now)

US9044402 ZYLA Abuse-deterrent pharmaceutical compositions for controlled release
Jul, 2033

(9 years from now)

Market Authorisation Date: 09 January, 2017

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of ARYMO ER before it's drug patent expiration?
More Information on Dosage

ARYMO ER family patents

Family Patents

2. Avinza patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6066339 KING PHARMS LLC Oral morphine multiparticulate formulation
Nov, 2017

(6 years ago)

Market Authorisation Date: 20 March, 2002

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of AVINZA before it's drug patent expiration?
More Information on Dosage

AVINZA family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Depodur patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5723147 PACIRA PHARMS INC Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
Mar, 2015

(9 years ago)

US5931809 PACIRA PHARMS INC Epidural administration of therapeutic compounds with sustained rate of release
Jul, 2015

(8 years ago)

US5807572 PACIRA PHARMS INC Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
Sep, 2015

(8 years ago)

US6193998 PACIRA PHARMS INC Method for producing liposomes with increased percent of compound encapsulated
Sep, 2016

(7 years ago)

US6241999 PACIRA PHARMS INC Method for producing liposomes with increased percent of compound encapsulated
Sep, 2016

(7 years ago)

US5997899 PACIRA PHARMS INC Method for producing liposomes with increased percent of compound encapsulated
Sep, 2016

(7 years ago)

US6171613 PACIRA PHARMS INC Method for producing liposomes with increased percent of compound encapsulated
Oct, 2016

(7 years ago)

US5891467 PACIRA PHARMS INC Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
Jan, 2017

(7 years ago)

US5962016 PACIRA PHARMS INC Multivesicular liposomes utilizing neutral lipids to modify in vivo release
Jan, 2017

(7 years ago)

Market Authorisation Date: 18 May, 2004

Treatment: Single-dose administration by the epidural route, at the lumbar level, for the treatment of pain following major surgery

Dosage: INJECTABLE, LIPOSOMAL;EPIDURAL

More Information on Dosage

DEPODUR family patents

Family Patents

4. Morphabond Er patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7955619 OHEMO LIFE Abuse resistant drugs, method of use and method of making
Aug, 2028

(4 years from now)

US10314788 OHEMO LIFE Pharmaceutical compositions configured to deter dosage form splitting
Aug, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-189) Oct 02, 2018

Market Authorisation Date: 02 October, 2015

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of MORPHABOND ER before it's drug patent expiration?
More Information on Dosage

MORPHABOND ER family patents

Family Patents

5. Morphine Sulfate patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9072781 FRESENIUS KABI USA Morphine formulations
Mar, 2034

(9 years from now)

US9192608 FRESENIUS KABI USA Morphine formulations
Mar, 2034

(9 years from now)

US9248229 FRESENIUS KABI USA Packaging system for oxygen-sensitive drugs
Mar, 2034

(9 years from now)

Market Authorisation Date: 30 October, 2013

Treatment: Treatment of pain

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS

More Information on Dosage

MORPHINE SULFATE family patents

Family Patents